Inaticabtagene autoleucel - Juventas Cell Therapy/CASI Pharmaceuticals
Alternative Names: Anti-CD19 CAR-T cell therapy - Juventas Cell Therapy; CNCT-19; HI19α-4-1BB-ζ CARLatest Information Update: 20 Sep 2024
At a glance
- Originator Chinese Academy of Medical Sciences
- Developer CASI Pharmaceuticals; Juventas Cell Therapy
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Precursor B-cell lymphoblastic leukaemia-lymphoma
- Phase II Non-Hodgkin's lymphoma
- Phase I/II Diffuse large B cell lymphoma
- No development reported B-cell lymphoma
Most Recent Events
- 13 Jun 2024 Efficacy and adverse event data from the phase I trial in Non-Hodgkin lymphoma presented at the 29th Congress of the European Haematology Association 2024 (EHA-2024)
- 20 Dec 2023 Phase-I clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (In children, In neonates, In infants) (IV) before December 2023 (CASI Pharmaceuticals pipeline, December 2023)
- 08 Nov 2023 Registered for Precursor B-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater, In adults) in China (IV)